News headlines about Maximus (NYSE:MMS) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Maximus earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the health services provider an impact score of 45.0802775011339 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- MAXIMUS Board of Directors Member Included in Savoy’s Most Influential Black Corporate Directors of 2017 (finance.yahoo.com)
- Richard A. Montoni Sells 10,000 Shares of Maximus, Inc. (MMS) Stock (americanbankingnews.com)
- Maximus, Inc. (MMS) CEO Richard A. Montoni Sells 30,000 Shares (americanbankingnews.com)
- Insider Selling: Maximus, Inc. (MMS) Insider Sells 5,000 Shares of Stock (americanbankingnews.com)
Maximus (MMS) traded up $0.07 during mid-day trading on Monday, reaching $70.89. 484,141 shares of the company’s stock were exchanged, compared to its average volume of 359,625. Maximus has a 12 month low of $51.74 and a 12 month high of $71.19. The firm has a market capitalization of $4,612.97, a PE ratio of 22.77, a P/E/G ratio of 2.66 and a beta of 1.35.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Wednesday, November 15th were issued a dividend of $0.045 per share. The ex-dividend date was Tuesday, November 14th. This represents a $0.18 dividend on an annualized basis and a yield of 0.25%. Maximus’s payout ratio is currently 5.66%.
Several analysts recently weighed in on the stock. Robert W. Baird reaffirmed a “hold” rating and issued a $64.00 target price on shares of Maximus in a report on Friday, September 1st. Zacks Investment Research cut shares of Maximus from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Finally, Canaccord Genuity cut their price objective on shares of Maximus from $62.00 to $61.00 and set a “hold” rating on the stock in a report on Friday, November 10th. Two research analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $64.33.
In other Maximus news, President Bruce Caswell sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $63.28, for a total transaction of $506,240.00. Following the sale, the president now owns 35,904 shares of the company’s stock, valued at $2,272,005.12. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Richard A. Montoni sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $69.25, for a total transaction of $2,077,500.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 103,717 shares of company stock worth $6,966,735. 3.10% of the stock is owned by corporate insiders.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.